<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01943318</url>
  </required_header>
  <id_info>
    <org_study_id>BRM_LC_Cohort</org_study_id>
    <nct_id>NCT01943318</nct_id>
  </id_info>
  <brief_title>Boramae Hospital Liver Cirrhosis Patient Cohort Study</brief_title>
  <official_title>Prospective Cohort Study to Evaluate Long-term Outcomes in Patients With Liver Cirrhosis of Boramae Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Boramae Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Boramae Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver cirrhosis represents a worldwide health problem and is a major cause of mortality.&#xD;
      Cirrhosis is the common end for chronic alcohol abuse and hepatitis C and B virus infections.&#xD;
      Patients who have cirrhosis have varying degrees of compensated liver function, and&#xD;
      clinicians need to differentiate between those who have stable, compensated cirrhosis and&#xD;
      those who have decompensated cirrhosis. It is shown various complications: portal&#xD;
      hypertension, hepatocellular carcinoma, hepato-renal syndrome, etc.&#xD;
&#xD;
      Thus, it is important to have this information to manage disease and determine specific&#xD;
      therapy. However, register-based studies in have not been reported in Korea.&#xD;
&#xD;
      The goal of this study is to describe the natural history of a large number of patients with&#xD;
      liver cirrhosis prospectively followed, and to identify predictors of the occurrence of&#xD;
      Hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are planning to recruit patients with liver cirrhosis, and collect the&#xD;
      baseline clinical laboratory data. Biological tests, endoscopy,liver ultrasonography&#xD;
      (including ARFI) and hepatic venous pressure gradient measurements will be performed if not&#xD;
      done within 90 days prior to inclusion. During this visit, 20 ml of blood will be collected&#xD;
      for freezing and storage of serum and plasma, and constitution of a DNA library.&#xD;
&#xD;
      Monitoring: Patients will have regular surveillance with blood test, liver ultrasonography&#xD;
      and medical consultation at least every 6 months, periodic assessment of esophageal, gastric&#xD;
      varices and portal hypertensive gastropathy (every 1 year) and prevention of their rupture if&#xD;
      any. An additional blood sampling of 20 ml will be taken at baseline and every year in order&#xD;
      to perform whole blood, serum, plasma, peripheral blood mononuclear cells and DNA libraries;&#xD;
      Data will be standardized and centralized in a single database.&#xD;
&#xD;
      And alcoholic liver cirrhosis patients will undergo liver biopsy for polymerase chain&#xD;
      reaction, western blot, immunohistochemistry and RNA analysis.&#xD;
&#xD;
      After measurement of hepatic venous pressure gradient and liver stiffness at baseline a&#xD;
      non-selective beta-blocker (NSBB,carvedilol) was initiated and increased stepwise (weekly)&#xD;
      until the systolic blood pressure remained at&gt;100 mmHg and the heart rate was not &lt;60. The&#xD;
      maximum target dose for carvedilol 25 mg/day. The hepatic venous pressure gradient response&#xD;
      to NSBB was again assessed 6 weeks after the intake of carvedilol. A hemodynamic response to&#xD;
      NSBB treatment was defined as a reduction in hepatic venous pressure gradient &gt;=20% compared&#xD;
      to baseline or to an absolute value &lt;=12 mmHg. Compliance with therapy was monitored by&#xD;
      monitoring of heart rate and blood pressure during clinical visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Liver-related outcome: Decompensated liver cirrhosis (ascites, variceal bleeding, hepatic encepahlopathy), occurence of hepatocellular carcinoma</measure>
    <time_frame>5 years</time_frame>
    <description>Cumulative incidence within 5 years Laboratory Tests: Albumin, Total bilirubin, prothrombin time, Platelet Hepatic venous pressure gradient measurement Imaging study like Liver CT or Liver ultrasonography Endoscopy for varix evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>5 years</time_frame>
    <description>overall mortality - whatever the cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver-related mortality</measure>
    <time_frame>5 years</time_frame>
    <description>cumulative incidence of liver-related deaths</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Alcohol</arm_group_label>
    <description>Alcoholic Liver Cirrhosis&#xD;
Participants will undergo liver biopsy. Participants will undergo hepatic venous pressure gradient measurement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis B virus</arm_group_label>
    <description>Hepatitis B virus (HBV) Liver Cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis C virus</arm_group_label>
    <description>Hepatitis C virus (HCV) Liver Cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autoimmune</arm_group_label>
    <description>Autoimmune Cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biliary</arm_group_label>
    <description>Primary or secondary biliary cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toxic</arm_group_label>
    <description>Medication related cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Others</arm_group_label>
    <description>Hepatic venous pressure gradient (HVPG) measurement</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver biopsy</intervention_name>
    <description>Histologic evaluation</description>
    <arm_group_label>Alcohol</arm_group_label>
    <arm_group_label>Autoimmune</arm_group_label>
    <arm_group_label>Biliary</arm_group_label>
    <arm_group_label>Hepatitis B virus</arm_group_label>
    <arm_group_label>Hepatitis C virus</arm_group_label>
    <arm_group_label>Others</arm_group_label>
    <arm_group_label>Toxic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hepatic venous pressure gradient (HVPG) measurement</intervention_name>
    <description>Hepatic venous pressure gradient (HVPG) measurement</description>
    <arm_group_label>Alcohol</arm_group_label>
    <arm_group_label>Autoimmune</arm_group_label>
    <arm_group_label>Biliary</arm_group_label>
    <arm_group_label>Hepatitis B virus</arm_group_label>
    <arm_group_label>Hepatitis C virus</arm_group_label>
    <arm_group_label>Others</arm_group_label>
    <arm_group_label>Toxic</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      At enrollement, 20 ml of blood will be collected for freezing and storage of serum and&#xD;
      plasma, and constitution of a DNA library&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Seoul National University Boramae hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥19years old Proven cirrhosis&#xD;
&#xD;
          -  No previous hepatocellular carcinoma (treated or not)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  serious associated short-term life threatening disease (except associated HIV viral&#xD;
             infection and the liver disease itself)&#xD;
&#xD;
          -  liver focal lesion suggestive of hepatocellular carcinoma&#xD;
&#xD;
          -  patient under guardianship&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  inability to regular monitoring, for whatever reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boramae Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SNU-SMG Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Dam Fialla A, Schaffalitzky de Muckadell OB, Touborg Lassen A. Incidence, etiology and mortality of cirrhosis: a population-based cohort study. Scand J Gastroenterol. 2012 Jun;47(6):702-9. doi: 10.3109/00365521.2012.661759. Epub 2012 Mar 19.</citation>
    <PMID>22428859</PMID>
  </reference>
  <reference>
    <citation>Reiberger T, Ferlitsch A, Payer BA, Pinter M, Homoncik M, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol. 2012 May;47(5):561-8. doi: 10.1007/s00535-011-0517-4. Epub 2011 Dec 15.</citation>
    <PMID>22170417</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 22, 2013</study_first_submitted>
  <study_first_submitted_qc>September 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2013</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Boramae Hospital</investigator_affiliation>
    <investigator_full_name>Won Kim</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

